News & Updates

Long-term exposure to elevated cumulative pulse pressure (cPP) potentially increases the risk of all-cause deaths, while prolonged exposure to elevated cumulative systolic blood pressure (cSBP) contributes to a higher risk of cardiovascular death, suggests a study.

A recent study suggests that successful treatment of depression alone is not enough to protect patients against the associated risk of cardiovascular disease (CVD).

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024. 

In most countries, Mondays have the highest risk of suicide during weekdays, while New Year’s and the consecutive days are associated with a risk increase, according to a study. On the other hand, suicide cases on weekends and Christmas vary by country and territory.

Children with homozygous familial hypercholesterolaemia (HoFH) achieve significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) with the microsomal triglyceride transfer protein (MTP) inhibitor lomitapide, which represents an efficient LDL receptor-independent treatment option, according to the open-label phase III APH-19 trial.

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.